Findings

What do systematic reviews say?

2,510 questions · 2,653 findings · 194 reviews · Gynaecology and Fertility

Sort:Best matchNewestHighest certainty Download CSV

No studies found 531 · 20%GRADE not reported 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%

Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)

Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome

Myo‐inositol showed no clear difference in adverse event ‐ multiple pregnancy compared with placebo, no/standard treatment (low certainty).

1 finding from 1 review

Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
OR 1.04 [0.63, 1.71]
2 studies · 425 participants
Low

Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)

Clinical pregnancy · subfertile women with polycystic ovary syndrome

It is very uncertain whether myo‐inositol changes clinical pregnancy compared with placebo, no/standard treatment (very low certainty).

1 finding from 1 review

Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
OR 1.27 [0.87, 1.85]
4 studies · 535 participants
Very low

Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)

Ovulation · subfertile women with polycystic ovary syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Myo‐inositol vs antioxidant (melatonin)

Live birth · subfertile women with polycystic ovary syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Myo‐inositol vs antioxidant (melatonin)

Adverse events ‐ Miscarriage · subfertile women with polycystic ovary syndrome

It is very uncertain whether myo‐inositol changes adverse event ‐ miscarriage compared with antioxidant (melatonin) (very low certainty).

1 finding from 1 review

Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
OR 0.7 [0.22, 2.24]
1 study · 358 participants
Very low

Myo‐inositol vs antioxidant (melatonin)

Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome

It is very uncertain whether myo‐inositol changes adverse event ‐ multiple pregnancy compared with antioxidant (melatonin) (very low certainty).

1 finding from 1 review

Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
OR 0.95 [0.57, 1.59]
1 study · 358 participants
Very low

Myo‐inositol vs antioxidant (melatonin)

Clinical pregnancy · subfertile women with polycystic ovary syndrome

It is very uncertain whether myo‐inositol changes clinical pregnancy compared with antioxidant (melatonin) (very low certainty).

1 finding from 1 review

Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
OR 0.83 [0.53, 1.28]
1 study · 358 participants
Very low

Transanal repair vs transvaginal repair

Outcomes ( · women with posterior vaginal wall prolapse

The review found no eligible studies for this question.

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Biological graft vs native tissue repair

Awareness of prolapse (subjective failure) (16‐24 months) · women with posterior vaginal wall prolapse

Biological graft showed no clear difference in awareness of prolapse (subjective failure) (16‐24 months) compared with native tissue repair (moderate certainty).

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
RR 1.09 [0.45, 2.62]
2 studies · 181 participants
Moderate

Biological graft vs native tissue repair

Repeat surgery for any prolapse (24 months) · women with posterior vaginal wall prolapse

Biological graft showed no clear difference in repeat surgery for any prolapse (24 months) compared with native tissue repair (low certainty).

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
RR 0.6 [0.18, 1.97]
2 studies · 271 participants
Low

Biological graft vs native tissue repair

Recurrent posterior vaginal wall prolapse (objective failure) (12‐25 months) · women with posterior vaginal wall prolapse

Biological graft showed no clear difference in recurrent posterior vaginal wall prolapse (objective failure) (16‐24… compared with native tissue repair (low certainty).

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
RR 0.55 [0.3, 1.01]
3 studies · 377 participants
Low

Biological graft vs native tissue repair

Postoperative obstructed defecation (16‐24 months) · women with posterior vaginal wall prolapse

Biological graft showed no clear difference in postoperative obstructed defecation (16‐24 months) compared with native tissue repair (moderate certainty).

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
RR 0.96 [0.5, 1.86]
2 studies · 172 participants
Moderate

Biological graft vs native tissue repair

Postoperative dyspareunia (12‐25 months) · women with posterior vaginal wall prolapse

Biological graft showed no clear difference in postoperative dyspareunia (16‐24 months) compared with native tissue repair (low certainty).

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
RR 1.26 [0.59, 2.68]
2 studies · 152 participants
Low

Biological graft vs native tissue repair

Postoperative complications (including wound infection) (16‐24 months) · women with posterior vaginal wall prolapse

Biological graft probably leads to higher postoperative complications (including wound infection) (16‐24 months) compared with native tissue repair (moderate certainty).

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
RR 1.82 [1.22, 2.72]
3 studies · 448 participants
Moderate

Biological graft vs native tissue repair

Operating time · women with posterior vaginal wall prolapse

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Low

Transanal repair vs transvaginal repair

Awareness of prolapse · women with posterior vaginal wall prolapse

Transanal repair showed no clear difference in awareness of prolapse (subjective failure) (12‐25 months) compared with transvaginal repair (low certainty).

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
RR 2.78 [1, 7.7]
2 studies · 87 participants
Low

Transanal repair vs transvaginal repair

Repeat surgery for any prolapse (25 months) · women with posterior vaginal wall prolapse

Transanal repair showed no clear difference in repeat surgery for any prolapse (25 months) compared with transvaginal repair (low certainty).

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
RR 2.42 [0.75, 7.88]
1 study · 57 participants
Low

Transanal repair vs transvaginal repair

Recurrent posterior vaginal wall prolapse (objective failure) (12‐25 months) · women with posterior vaginal wall prolapse

Transanal repair probably leads to higher recurrent posterior vaginal wall prolapse (objective failure) (12‐25… compared with transvaginal repair (moderate certainty).

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
RR 4.12 [1.56, 10.88]
2 studies · 87 participants
Moderate

Transanal repair vs transvaginal repair

Postoperative obstructed defecation (6‐25 months) · women with posterior vaginal wall prolapse

Transanal repair showed no clear difference in postoperative obstructed defecation (6‐25 months) compared with transvaginal repair (low certainty).

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
RR 1.67 [1, 2.79]
3 studies · 113 participants
Low

Transanal repair vs transvaginal repair

Postoperative dyspareunia (12‐25 months) · women with posterior vaginal wall prolapse

Transanal repair showed no clear difference in postoperative dyspareunia (12‐25 months) compared with transvaginal repair (low certainty).

1 finding from 1 review

Surgery for women with posterior compartment prolapse 2018 · Cochrane Headline outcomes only
RR 0.32 [0.09, 1.15]
2 studies · 80 participants
Low